The Medical Letter on Drugs and Therapeutics
Ipilimumab (Yervoy) for Metastatic Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ipilimumab (Yervoy – Bristol-Myers Squibb), a recombinant human monoclonal antibody, for treatment of unresectable or metastatic melanoma.

MECHANISM OF ACTION — Ipilimumab blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of the immune system, thus potentiating a T-cell mediated antitumor immune response.

STANDARD TREATMENT — Treatment options for unresectable or metastatic melanoma are limited. Dacarbazine (DTIC) is generally used, but has not shown a survival benefit. High-dose interleukin-2 (aldesleukin; Proleukin) therapy has produced responses in 16% of patients and a complete response in 6%; five years later, none of the responding patients had experienced disease progression. Severe toxicity has, however, limited its use.1 Addition of a gp100 peptide vaccine to high-dose ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ipilimumab (Yervoy) for Metastatic Melanoma
Article code: 1367c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian